Literature DB >> 11959089

Effect of a BLT receptor antagonist in a model of severe ischemia and reperfusion injury in the rat.

Danielle G Souza1, Vanessa Pinho, Giovanni D Cassali, Stephen Poole, Mauro M Teixeira.   

Abstract

Pharmacological strategies which limit neutrophil recruitment may also limit the damage induced by the reperfusion of an ischemic vascular territory. In the present study, we have investigated the effects of the BLT receptor antagonist, CP-105,696 ((+)-1-(3S,4R)-[3-(4-phenyl-benzyl)-4-hydroxy-chroman-7-yl]-cyclopentane carboxylic acid), on the local, remote and systemic inflammatory changes observed during severe intestinal ischemia (120 min) and reperfusion (120 min) injury. The post-ischemic treatment with CP-105,696 (3 mg/kg) virtually abolished the increase in vascular permeability, but not neutrophil accumulation, in the intestine and lungs. CP-105,696 partially inhibited the reperfusion-induced neutropenia, but failed to affect intestinal haemorrhage or lethality. CP-105,696 had no inhibitory effect on the local and systemic increases in the concentrations of tumour necrosis factor (TNF-alpha), interleukin-1 beta and interleukin-10, but markedly suppressed interleukin-6. Overall, our results show that activation of BLT receptor plays a minor role in the local, remote and systemic injuries following severe ischemia and reperfusion in rats.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959089     DOI: 10.1016/s0014-2999(02)01313-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury.

Authors:  Danielle G Souza; Riccardo Bertini; Angelica T Vieira; Fernando Q Cunha; Steve Poole; Marcello Allegretti; Francesco Colotta; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

2.  Cooperative role of tumour necrosis factor-α, interleukin-1β and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice.

Authors:  Daniela Sachs; Fernanda M Coelho; Vívian V Costa; Fernando Lopes; Vanessa Pinho; Flávio A Amaral; Tarcília A Silva; Antônio L Teixeira; Daniele G Souza; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major.

Authors:  Helton da Costa Santiago; Carolina Ferreira Oliveira; Luciana Santiago; Fernanda Oliveira Ferraz; Daniele da Glória de Souza; Luiz Antônio Rodrigues de-Freitas; Luís Carlos Crocco Afonso; Mauro Martins Teixeira; Ricardo Tostes Gazzinelli; Leda Quercia Vieira
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

4.  Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats.

Authors:  Caroline Bélanger; Hanan Elimam; Julie Lefebvre; Pierre Borgeat; Sylvie Marleau
Journal:  Immunology       Date:  2008-01-24       Impact factor: 7.397

5.  Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury.

Authors:  Danielle G Souza; Vanessa Pinho; Jorge L Pesquero; Eliane S Lomez; Steve Poole; Luiz Juliano; Ary Correa; M Salete de A Castro; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects.

Authors:  Priscila T T Bernardes; Bárbara M Rezende; Carolina B Resende; Talles P De Paula; Alesandra C Reis; William A Gonçalves; Elias G Vieira; Maurício V B Pinheiro; Danielle G Souza; Marina G M Castor; Mauro M Teixeira; Vanessa Pinho
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

7.  Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.

Authors:  Rodrigo D Carvalho; Natalia Breyner; Zelia Menezes-Garcia; Nubia M Rodrigues; Luisa Lemos; Tatiane U Maioli; Danielle da Gloria Souza; Denise Carmona; Ana M C de Faria; Philippe Langella; Jean-Marc Chatel; Luis G Bermúdez-Humarán; Henrique C P Figueiredo; Vasco Azevedo; Marcela S de Azevedo
Journal:  Microb Cell Fact       Date:  2017-02-13       Impact factor: 5.328

8.  Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.

Authors:  Barbara Maximino Rezende; Rayssa Maciel Athayde; William Antônio Gonçalves; Carolina Braga Resende; Priscila Teles de Tolêdo Bernardes; Denise Alves Perez; Lísia Esper; Alesandra Côrte Reis; Milene Alvarenga Rachid; Marina Gomes Miranda E Castor; Thiago Mattar Cunha; Fabiana Simão Machado; Mauro Martins Teixeira; Vanessa Pinho
Journal:  J Exp Med       Date:  2017-09-25       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.